EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY 4.0

Extended Insights Into Advancing Multi-Omics and Prognostic Methods for Cancer Prognosis Forecasting

Jindong Xie, Junjie Xu, Zhi Tian, Jian Liang, Hailin Tang

Frontiers in Bioscience-Landmark · 30.08.2025 · 30 (8)

DOI: 10.31083/fbl44091 ↗

Kurz gefasst

Editorial in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 30.08.2025. Verfasst von Jindong Xie und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, 5100…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Biomarkers, Tumor, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zhang et al.’s recent article utilizes comprehensive single-cell data to identify differences in tumor cell populations, highlighting the CKS1B+ malignant cell subcluster as a potential target for immunotherapy. It develops a prognostic and immunotherapeutic signature (PIS) based on this subcluster, demonstrating good performance in predicting lung adenocarcinoma (LUAD) prognosis. The study also validates the role of PSMB7 in LUAD progression. However, there are areas for improvement. There is a lack of clarity regarding the relationship between the CKS1B+ malignant cell subcluster and the PIS, particularly in terms of why PSMB7 was selected for functional studies. The sequencing data are retrospectively obtained from public databases and lack prospective clinical validation. It is suggested to collect LUAD patient tissues for RT-qPCR and RNA-seq analysis and seek external multi-center validations. Additionally, integrating emerging multi-omics methods is recommended to further validate the findings. Despite these limitations, the study represents progress in understanding LUAD and treatment strategies, and continuous evaluation and refinement of multi-omics and machine learning methods are expected for future research and clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungBiomarkers, TumorLung NeoplasmsHumansGene Expression Regulation, NeoplasticGenomicsMultiomicsPrognosis

Stichwörter der Autor:innen

cancermachine learningmulti-omicsprognosis

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, 510060 Guangzhou, Guangdong, China.
  • Department of Molecular Pharmacology & Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.
  • School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, 510006 Guangzhou, Guangdong, China.

Zitieren

APA

Xie, J., Xu, J., Tian, Z., Liang, J., & Tang, H. (2025). Extended Insights Into Advancing Multi-Omics and Prognostic Methods for Cancer Prognosis Forecasting. Frontiers in Bioscience-Landmark, 30(8). https://doi.org/10.31083/fbl44091

Vancouver

Xie J, Xu J, Tian Z, Liang J, Tang H. Extended Insights Into Advancing Multi-Omics and Prognostic Methods for Cancer Prognosis Forecasting. Frontiers in Bioscience-Landmark. 2025;30(8). doi:10.31083/fbl44091

BibTeX
@article{Xie2025,
  author = {Xie, Jindong and Xu, Junjie and Tian, Zhi and Liang, Jian and Tang, Hailin},
  title = {Extended Insights Into Advancing Multi-Omics and Prognostic Methods for Cancer Prognosis Forecasting},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2025},
  volume = {30},
  number = {8},
  doi = {10.31083/fbl44091}
}
Kostenlos starten →